Welcome to our dedicated page for Immunome news (Ticker: IMNM), a resource for investors and traders seeking the latest updates and insights on Immunome stock.
Immunome, Inc. develops targeted cancer therapies through a clinical-stage oncology pipeline that includes varegacestat, an investigational oral gamma secretase inhibitor for desmoid tumors, IM-1021, a ROR1 antibody-drug conjugate, and IM-3050, a FAP-targeted radiotherapy. Company news commonly covers clinical data, regulatory submissions, IND-related progress, oncology conference presentations, and updates on antibody-drug conjugate programs for solid tumors.
Recurring corporate updates also include financial results, business progress reports, investor conference participation, equity compensation actions under the 2024 Inducement Plan, and Nasdaq Listing Rule 5635(c)(4) inducement grants for new employees.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Immunome, Inc. (Nasdaq: IMNM) reported its financial results for Q4 2022, revealing a net loss of $7.8 million, or $0.64 per share, against a total net loss of $36.9 million, or $3.09 per share, for the year. As of December 31, 2022, the company held $20.3 million in cash and equivalents. A noteworthy highlight includes a strategic collaboration with AbbVie, initiating the discovery of up to 10 novel antibody-target pairs, valued at up to $120 million per target. Additionally, preclinical data for its anti-EPN1 antibody showed promising results, indicating a significant tumor volume reduction when combined with existing treatments.
Immunome (Nasdaq: IMNM) announces that Chief Technology Officer Matthew Robinson, Ph.D., will present at the 13th Annual World ADC London conference from March 13-16, 2023. Dr. Robinson's talk on March 15 will focus on Immunome's Discovery Engine, a platform that uses human memory B cells to identify novel therapeutic targets for antibody-drug conjugates (ADCs). This proprietary technology aims to enhance cancer treatments by finding proteins selectively expressed on cancer cells. A copy of the presentation will be available post-event on Immunome's website.
Immunome, Inc. (NASDAQ: IMNM) has established an advisory board featuring Dr. John Lambert and Dr. Anthony Tolcher to enhance the prioritization of novel targets for antibody drug conjugates (ADCs) and T cell redirection (TCR) modalities. These treatment modalities are becoming increasingly significant in oncology. Lambert emphasized the importance of identifying next-generation targets for successful ADC and TCR development, while Tolcher noted the growing clinical interest following recent FDA approvals. Immunome's proprietary Discovery Engine continues to uncover potential tumor-selective targets, aiming to broaden therapeutic options for cancer treatments.
Immunome has entered a multi-year collaboration with AbbVie to discover up to 10 novel target-antibody pairs through Immunome’s Discovery Engine. This agreement includes a $30M upfront payment and potential further payments totaling up to $70M for platform access, along with development milestones of up to $120M per target. AbbVie aims to enhance its oncology pipeline with Immunome’s innovative technology, which leverages human memory B cells for effective cancer therapeutics.